271. Ankylosing spondylitis Clinical trials / Disease details
Clinical trials : 574 / Drugs : 359 - (DrugBank : 68) / Drug target genes : 41 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05407246 (ClinicalTrials.gov) | June 24, 2022 | 30/5/2022 | Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study on the Efficacy and Safety of hemay005 Tablets in the Treatment of Active Ankylosing Spondylitis | Active Ankylosing Spondylitis | Drug: Hemay005 | Tianjin Hemay Pharmaceutical Co., Ltd | NULL | Not yet recruiting | 18 Years | 65 Years | All | 90 | Phase 2 | China |